-
公开(公告)号：IL291073D0
公开(公告)日：2022-05-01
申请号：IL29107322
申请日：2022-03-02
Applicant: ABBVIE INC , BOGHAERT ERWIN R , SOUERS ANDREW J , PHILLIPS ANDREW C , JUDD ANDREW S , BRUNCKO MILAN
Inventor： BOGHAERT ERWIN R , SOUERS ANDREW J , PHILLIPS ANDREW C , JUDD ANDREW S , BRUNCKO MILAN
Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
-
公开(公告)号：IL287315D0
公开(公告)日：2021-12-01
申请号：IL28731521
申请日：2021-10-17
Applicant: ABBVIE INC , TAO ZHI FU , WANG XILU , WENDT MICHAEL , SOUERS ANDREW J , JUDD ANDREW S , KUNZER AARON , SULLIVAN GERARD
Inventor： TAO ZHI-FU , WANG XILU , WENDT MICHAEL , SOUERS ANDREW J , JUDD ANDREW S , KUNZER AARON , SULLIVAN GERARD
IPC: A61K31/496 , A61K31/5377 , A61K45/06 , A61P35/00 , A61P37/00
Abstract: Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
-
公开(公告)号：IL291073A
公开(公告)日：2022-05-01
申请号：IL29107322
申请日：2022-03-02
Applicant: ABBVIE INC , BOGHAERT ERWIN R , SOUERS ANDREW J , PHILLIPS ANDREW C , JUDD ANDREW S , BRUNCKO MILAN
Inventor： BOGHAERT ERWIN R , SOUERS ANDREW J , PHILLIPS ANDREW C , JUDD ANDREW S , BRUNCKO MILAN
Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
-
公开(公告)号：IL312709A
公开(公告)日：2024-07-01
申请号：IL31270924
申请日：2024-05-08
Applicant: ABBVIE INC , BHAT VIKRAM , BRADY PATRICK , DAI YUJIA , DOHERTY GEORGE A , GONG JIANCHUN , JUDD ANDREW S , SOUERS ANDREW J , YU YIYUN
Inventor： BHAT VIKRAM , BRADY PATRICK , DAI YUJIA , DOHERTY GEORGE A , GONG JIANCHUN , JUDD ANDREW S , SOUERS ANDREW J , YU YIYUN
IPC: A61P35/02
Abstract: The present invention provides for compounds of Formula (I)wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
-
公开(公告)号：IL282594D0
公开(公告)日：2021-06-30
申请号：IL28259421
申请日：2021-04-22
Applicant: ABBVIE INC , TAO ZHI FU , DOHERTY GEORGE , WANG XILU , SONG XIAOHONG , SULLIVAN GERARD M , KUNZER AARON , WENDT MICHAEL , MARIN VIOLETA L , FREY ROBIN R , CULLEN STEVE C , WELCH DENNIE S , SHEN XIAOQIANG , BENNETT DAVID JONATHAN , HAIGHT ANTHONY R , ACKLER SCOTT L , BOGHAERT ERWIN R , SOUERS ANDREW J , JUDD ANDREW S
Inventor： TAO ZHI-FU , DOHERTY GEORGE , WANG XILU , SONG XIAOHONG , SULLIVAN GERARD M , KUNZER AARON , WENDT MICHAEL , MARIN VIOLETA L , FREY ROBIN R , CULLEN STEVE C , WELCH DENNIE S , SHEN XIAOQIANG , BENNETT DAVID JONATHAN , HAIGHT ANTHONY R , ACKLER SCOTT L , BOGHAERT ERWIN R , SOUERS ANDREW J , JUDD ANDREW S
IPC: A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/4985 , A61K31/538 , A61K45/06 , A61K47/68 , A61P35/00 , A61P35/02 , A61P43/00
Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
-
Patent Agency Ranking
公开(公告)号：IL263600D0
公开(公告)日：2019-01-31
申请号：IL26360018
申请日：2018-12-09
Applicant: ABBVIE INC , BENATUIL LORENZO , BRUNCKO MILAN , CHAO DEBRA , IZERADJENE KAMEL , JUDD ANDREW S , PHILLIPS ANDREW C , SOUERS ANDREW J , THAKUR ARCHANA
Inventor： BENATUIL LORENZO , BRUNCKO MILAN , CHAO DEBRA , IZERADJENE KAMEL , JUDD ANDREW S , PHILLIPS ANDREW C , SOUERS ANDREW J , THAKUR ARCHANA
IPC: C07K20060101
Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：IL263571D0
公开(公告)日：2019-01-31
申请号：IL26357118
申请日：2018-12-07
Applicant: ABBVIE INC , BOGHAERT ERWIN R , SOUERS ANDREW J , PHILLIPS ANDREW C , JUDD ANDREW S , BRUNCKO MILAN
Inventor： BOGHAERT ERWIN R , SOUERS ANDREW J , PHILLIPS ANDREW C , JUDD ANDREW S , BRUNCKO MILAN
IPC: A61K20060101
Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
-
8.发明申请PYRIDAZINO [4, 5 -D] PYRIMIDIN- (6H) -ONE INHIBITORS OF WEE - 1 KINASE 审中-公开吡啶并[4，5 -D]嘧啶 - （6H） - 酮抑制剂
公开(公告)号：WO2013013031A1
公开(公告)日：2013-01-24
申请号：PCT/US2012/047381
申请日：2012-07-19
Applicant: ABBVIE INC. , ZHU, Guidong , GONG, Jane , JUDD, Andrew S. , GHANDI, Virajkumar B. , SHOEMAKER, Alexander R. , PENNING, Thomas D. , MICHAELIDES, Michael R. , LAI, Chunqiu , WOODS, Keith W.
Inventor： ZHU, Guidong , GONG, Jane , JUDD, Andrew S. , GHANDI, Virajkumar B. , SHOEMAKER, Alexander R. , PENNING, Thomas D. , MICHAELIDES, Michael R. , LAI, Chunqiu , WOODS, Keith W.
IPC: C07D487/04 , A61K31/519 , A61P35/00
CPC classification number: C07D487/04
Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, Formula (I) wherein B, R 1 , R 2 , R 4 , and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，式（I）其中B，R 1，R 2，R 4和m在说明书中定义。 本发明还涉及含有所述化合物的组合物，其可用于抑制诸如wee-1的激酶和治疗诸如癌症的疾病的方法。
-
公开(公告)号：WO2007137107A3
公开(公告)日：2008-01-10
申请号：PCT/US2007069112
申请日：2007-05-17
Applicant: ABBOTT LAB , IYENGAR RAJESH R , ZHAO GANG , FREEMAN JENNIFER C , GAO JU , JUDD ANDREW S , KYM PHILIP R , LYNCH JOHN K , MULHERN MATHEW M , SOUERS ANDREW J
Inventor： IYENGAR RAJESH R , ZHAO GANG , FREEMAN JENNIFER C , GAO JU , JUDD ANDREW S , KYM PHILIP R , LYNCH JOHN K , MULHERN MATHEW M , SOUERS ANDREW J
IPC: C07C211/22 , A61K31/155 , A61K31/17 , A61K31/381 , A61K31/4164 , A61K31/435 , A61P3/04 , C07C275/30 , C07C279/18 , C07C335/16 , C07D213/55 , C07D213/75 , C07D277/28 , C07D333/36
CPC classification number: C07C335/22 , C07C229/46 , C07C275/30 , C07C275/32 , C07C275/38 , C07C279/28 , C07C2601/08 , C07C2601/14 , C07D213/55 , C07D213/75 , C07D277/30 , C07D333/22 , C07D333/36 , C07D401/04 , C07D401/12 , C07D409/12 , C07D409/14
Abstract: The present invention relates to compounds of formula (I) wherein R 1 , R 3 , X, Q, Z, A, D, m, and n are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
Abstract translation: 本发明涉及式（I）化合物，其中R 1，R 3，X，Q，Z，A，D，m和n如本文所定义。 还公开了治疗DGAT-1相关疾病或病症的药物组合物和方法。
-
10.发明申请PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) 审中-公开作为DIPPTIDYL PEPTIDASE-IV（DPP-IV）抑制剂的药物组合物
公开(公告)号：WO2007027651A2
公开(公告)日：2007-03-08
申请号：PCT/US2006033620
申请日：2006-08-25
Applicant: ABBOTT LAB , PEI ZHONGHUA , VON GELDERN THOMAS , MADAR DAVID J , LI XIAOFENG , BASHA FATIMA , YONG HONG , LONGENECKER KENTON L , BACKES BRADLEY J , JUDD ANDREW S , MULHERN MATHEW M , STEWART KENT D
Inventor： PEI ZHONGHUA , VON GELDERN THOMAS , MADAR DAVID J , LI XIAOFENG , BASHA FATIMA , YONG HONG , LONGENECKER KENTON L , BACKES BRADLEY J , JUDD ANDREW S , MULHERN MATHEW M , STEWART KENT D
IPC: C07C217/54 , C07C211/40 , C07D213/38 , C07D213/68 , C07D317/64
CPC classification number: C07C211/48 , C07C211/40 , C07C217/52 , C07C217/54 , C07C217/74 , C07C217/84 , C07C217/86 , C07C225/22 , C07C229/42 , C07C229/48 , C07C229/60 , C07C233/43 , C07C233/78 , C07C235/46 , C07C237/24 , C07C237/30 , C07C237/42 , C07C255/54 , C07C255/58 , C07C311/22 , C07C311/36 , C07C317/22 , C07C317/36 , C07C2601/14 , C07C2601/16 , C07D207/16 , C07D209/08 , C07D209/48 , C07D211/46 , C07D211/60 , C07D211/62 , C07D213/30 , C07D213/38 , C07D213/64 , C07D213/68 , C07D213/74 , C07D213/82 , C07D217/04 , C07D263/56 , C07D263/60 , C07D277/04 , C07D277/64 , C07D295/135 , C07D295/185 , C07D295/205 , C07D317/66 , C07D319/18 , C07D333/34 , C07D333/38 , C07D409/04 , C07D487/04 , C07D491/048 , C07D495/04 , C07D498/04 , C07D513/04
Abstract: The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，代谢综合征，高胰岛素血症，肥胖症，动脉粥样硬化，各种免疫调节疾病 ，等疾病。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.024 seconds)
